Efficacy and safety of fesoterodine fumarate in neurogenic detrusor overactivity due to spinal cord lesion (SCL) or multiple sclerosis (MS)
Latest Information Update: 28 Oct 2022
At a glance
- Drugs Fesoterodine (Primary)
- Indications Overactive bladder
- Focus Therapeutic Use
- 01 Nov 2021 Results (n=124) assessing the efficacy of fesoterodine fumarate on patients with neurogenic detrusor overactivity due to spinal cord lesion or multiple sclerosis, published in the Neurourology and Urodynamics.
- 13 Sep 2021 Primary endpoint (change from baseline to end of treatment in maximum detrusor pressure (Pdetmax) during the filling phase of the UDS and whether the use of Fesoterodine fumarate would decrease it) has been met according to the results presented at the 116th Annual Meeting of the American Urological Association
- 13 Sep 2021 Results assessing the efficacy of Fesoterodine fumarate on patients with nDO due to Spinal Cord Lesion(SCL) or Multiple sclerosis (MS) presented at the 116th Annual Meeting of the American Urological Association